28 Mar 2023
Midatech Pharma - Development pipeline expands with MTD217
Midatech has announced a new preclinical programme, MTD217, targeting leptomeningeal disease, a secondary metastatic cancer of the central nervous system (CNS), with currently poor prognosis (average survival of 3–6 months). The drug will be developed using the MidaSolve platform (dissolves otherwise insoluble drugs that can then be injected directly to the site of the cancer to maximise efficacy and reduce off-target toxicity). Midatech is working on initiating preclinical studies (in collabora ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Midatech Pharma - Development pipeline expands with MTD217
- Published:
28 Mar 2023 -
Author:
Dr Adam McCarter -
Pages:
2
Midatech has announced a new preclinical programme, MTD217, targeting leptomeningeal disease, a secondary metastatic cancer of the central nervous system (CNS), with currently poor prognosis (average survival of 3–6 months). The drug will be developed using the MidaSolve platform (dissolves otherwise insoluble drugs that can then be injected directly to the site of the cancer to maximise efficacy and reduce off-target toxicity). Midatech is working on initiating preclinical studies (in collabora ....